Luis Fernando Silveira

Dr. Luis Fernando Silveira

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2011 in Vaccine
Verified
Journal Article
Closed access
GMGabriela Maggioli
Gabriela Maggioli
DADaniel Acosta
Daniel Acosta
LSLuis Fernando Silveira
Luis Fernando Silveira
SRSilvina Rossi
Silvina Rossi
SGSheila Giacaman
Sheila Giacaman
CCCarlos Carmona
Carlos Carmona

20 March 2012 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
SVSimone Verza
Simone Verza
LSLuis Fernando Silveira
Luis Fernando Silveira
SCSamuel Cibulski
Samuel Cibulski
SKSamuel Kaiser
Samuel Kaiser
FFFernando Ferreira
Fernando Ferreira
GOGeorge G. Ortega
George G. Ortega

1 February 2016 in Vaccine
Verified
Journal Article
Closed access
SCSamuel Paulo Cibulski
Samuel Paulo Cibulski
GMGustavo Mourglia-Ettlin
Gustavo Mourglia-Ettlin
TTThais Fumaco Teixeira
Thais Fumaco Teixeira
LQLenora Quirici
Lenora Quirici
PRPaulo Michel Roehe
Paulo Michel Roehe
LSLuis Fernando Silveira
Luis Fernando Silveira

11 September 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SCSamuel Paulo Cibulski
Samuel Paulo Cibulski
MRMariana Rivera-Patron
Mariana Rivera-Patron
GMGustavo Mourglia-Ettlin
Gustavo Mourglia-Ettlin
CCCecilia Casaravilla
Cecilia Casaravilla
AYAnna Carolina Alves Yendo
Anna Carolina Alves Yendo
LSLuis Fernando Silveira
Luis Fernando Silveira
Commercially available saponins are extracted from Quillaja saponaria barks, being Quil A® the most widely used. Nanoparticulate immunostimulating complexes (ISCOMs or ISCOMATRIX) formulated with these, are able to stimulate strong humoral and cellular immune responses. Recently, we formulated novel ISCOMs replacing QuilA® by QB-90 (IQB-90), a Quillaja brasiliensis leaf-extracted saponin fraction, and reported that IQB-90 improved antigen uptake, and induced systemic and mucosal antibody production, and T-cell responses. However, its mechanism of action remains unclear. In this study we provide a deeper insight into the immune stimulatory properties of QB-90 and ISCOMATRIX-like based on this fraction (IMXQB-90). We show herein that, when used as a viral vaccine adjuvant, QB-90 promotes an “immunocompetent environment”. In addition, QB-90 and IMXQB-90 induce immune-cells recruitment at draining-lymph nodes and spleen. Subsequently, we prove that QB-90 or IMXQB-90 stimulated dendritic cells secret IL-1β by mechanisms involving Caspase-1/11 and MyD88 pathways, implying canonical inflammasome activation. Finally, both formulations induce a change in the expression of cytokines and chemokines coding genes, many of which are up-regulated. Findings reported here provide important insights into the molecular and cellular mechanisms underlying the adjuvant activity of Q. brasiliensis leaf-saponins and its respective nanoparticles.

1 November 2011 in Vaccine
Verified
Journal Article
Closed access
LSLuis Fernando Silveira
Luis Fernando Silveira
SCS.P. Cibulski
S.P. Cibulski
AVA.P. Varela
A.P. Varela
JMJ.M. Marqués
J.M. Marqués
ACA. Chabalgoity
A. Chabalgoity
FFF. Ferreira
F. Ferreira

1 January 2018 in Vaccine
Verified
Journal Article
Closed access
SCSamuel Cibulski
Samuel Cibulski
MRMariana Rivera-Patron
Mariana Rivera-Patron
NSNorma Suarez
Norma Suarez
MPMacarena Pirez
Macarena Pirez
SRSilvina Rossi
Silvina Rossi
LSLuis Fernando Silveira
Luis Fernando Silveira